Skip to main content

Table S1 Patients characteristic

From: Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms

NO.

Gender

Age

WBC(*109/L)

Hb (g/L)

PLT (*109/L)

FAB type

BM Blasts(%)

Immune markers

Karyotype

1

female

23

1.85

124

168

M0

63.2

CD7, CD117, HLA-DR

46 XX

2

male

29

12.72

138

7

M5

60.3

CD7,HLA-DR, CD33

46 XY

3

male

32

1.14

46

4

M2a

80

MPO,CD99,CD117

46 XY t(8;21)

4

female

36

5.57

50

83

M5b

78

CD117, CD33,MPO

46 XX

5

female

43

20.57

45

10

M1

72

CD117, CD33, MPO

46 XX

6

female

25

19.6

34

23

M0

69.3

CD7, CD117, MPO

46 XX

7

male

29

27

23

3

M5

59.6

CD33, HLA-DR CD15

46 XY

  1. NO.1-4 were used to FCM (Flow Cytometry) analysis; NO.5-7 were used to synergistic effect. NO.7 were also used for WB